Cyclotrons Close the Gap on Nuclear Reactors as Hospitals Make Their Own PET Tracers

0
7

The Radiopharmaceuticals Market was valued at USD 8.63 billion in 2025 and is expected to reach USD 9.52 billion in 2026. It is projected to climb to USD 21.10 billion by 2034, a CAGR of 10.4%. The rising number of cancer and cardiovascular cases, together with an aging global population, is the main force behind this growth. North America led in 2025 with a 45.0% share, supported by advanced nuclear medicine infrastructure and strong investment in precision medicine and oncology research.

What Radiopharmaceuticals Do

Radiopharmaceuticals are compounds containing radioactive isotopes. They are used in diagnostic imaging such as PET and SPECT scans, and in therapies that treat specific cancers. Diagnostic products emit gamma rays or positrons at low doses so that tracers collecting in organs and tissues can be detected by imaging systems. Therapeutic products emit beta or alpha particles at higher doses to destroy diseased cells while limiting harm to healthy tissue. Isotopes such as technetium-99m and fluorine-18 dominate diagnostics, while iodine-131, lutetium-177, yttrium-90 and radium-223 are used in treatment.

Disease Burden and Demographics

The World Health Organization expects chronic conditions, including cardiovascular disease and cancer, to account for 86% of a projected 90 million annual deaths by 2050. Cancer detection and cardiac imaging increasingly depend on nuclear medicine for staging, treatment monitoring and risk assessment. Aging adds to this pressure. The WHO projects that one in six people worldwide will be 60 or older by 2030, and that this group will double to 2.1 billion by 2050. Older adults face higher risks of neurodegenerative disorders, cancer and heart disease, which raises procedural volumes for both diagnostic and therapeutic radiopharmaceuticals.

Innovation and Collaboration

Partnerships between pharmaceutical companies and research institutions are accelerating new products. In April 2025, Debiopharm and Oncodesign Services collaborated on antibody–chelator conjugates for radioimmunotherapy targeting HER2-positive tumors. In July 2025, the University of Alberta developed a radiotracer that improves breast cancer detection through faster, more accurate scans. Better supply chains and government support for nuclear medicine research are adding further momentum.

The AI Effect

AI is reshaping the industry in several ways. It speeds up radiotracer discovery and molecular design, improves the reading of PET and SPECT scans, and supports patient-specific dosimetry for targeted radionuclide therapy. It also helps forecast demand and schedule isotope production, which matters because many isotopes decay quickly. Clinicians use AI-based tools to support diagnosis, monitor treatment and predict therapy response.

Segment Highlights

By radioisotope, technetium-99 led with 26.0% of revenue in 2025. Its short half-life, cost efficiency and suitable gamma emission make it a staple of SPECT imaging for bone, cardiac and oncology work. Fluorine-18 is expected to grow fastest at 10.0%, driven by PET demand and its use in FDG, which shows metabolic activity in tissue with high precision.

By application, oncology held the largest share at 39.0% as tumor detection, staging and targeted radiation therapy become more common. Neurology is projected to grow fastest at 9.5%, with radiotracers increasingly used for early diagnosis and monitoring of Alzheimer’s and Parkinson’s disease.

By source, nuclear reactors held 68.0% in 2025 because isotopes such as molybdenum-99, which decays into technetium-99m, are essential for most diagnostic imaging. Cyclotrons are expected to grow fastest at 10.1%, as hospital-based units offer cost efficiency, production of shorter-lived isotopes and less dependence on reactors.

By end user, hospitals led with 45.0% thanks to high procedure volumes and integrated nuclear medicine departments. Diagnostic centers are projected to grow fastest at 10.0%. US Radiology Specialists, for example, has been opening new imaging centers as part of a network of 183 sites across 13 states, with growing use of PET-CT and SPECT systems.

Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/radiopharmaceuticals-market

Regional Outlook

In the United States, which held 89.96% of the North American market in 2025, the American Cancer Society projects over 2 million new cancer cases, sustaining demand for molecular-level diagnostics. Asia Pacific is expected to grow at 10.2% as India, China and South Korea expand healthcare infrastructure and add nuclear medicine departments. China is forecast to grow at 11.0%, helped by national investment in nuclear technology and cancer control programs. Europe is projected to hold 29.0% by 2034, supported by early detection programs and initiatives such as the PRISMAP project, which links 23 institutions across 13 countries to advance medical radionuclide development.

Competitive Landscape and Deals

The market is moderately consolidated, with competition centered on isotope innovation, precision targeting and therapeutic effectiveness. Theranostics, which pairs diagnosis with personalized treatment in a single workflow, is gaining traction. Key players include Bayer, AstraZeneca, GE HealthCare, Curium, Lantheus, Cardinal Health, Bracco Imaging, Eckert & Ziegler, Jubilant Radiopharma, Eli Lilly, Roche, GSK, Boehringer Ingelheim, Mallinckrodt and Advanced Accelerator Applications.

Recent deals show the sector’s momentum. Telix Pharmaceuticals agreed in September 2026 to acquire ITM Isotope Technologies Munich for about USD 1.65 billion upfront. In August 2026, Curium agreed to acquire Lantheus in a deal worth up to USD 8 billion. Aktis Oncology raised about USD 318 million in a January 2026 IPO backed by Eli Lilly, and GE HealthCare’s PET cardiac tracer Flyrcado gained FDA approval and CMS reimbursement for outpatient use.

Challenges

Short shelf life forces rapid production, distribution and administration. High production costs, tied to expensive isotopes and cyclotron or reactor facilities, and complex regulation of radioactive materials slow commercialization. Limited PET and SPECT infrastructure also restricts access in developing regions.

Radiopharmaceuticals Market growth through 2034 will depend on how effectively the industry solves supply, cost and access problems while expanding clinical use. As theranostics matures, cyclotron networks widen and AI sharpens imaging and dosing, radiopharmaceuticals are set to become a core part of precision oncology, cardiology and neurology. Companies that secure reliable isotope supply and build strong clinical partnerships will be best positioned to lead.

More Trending Latest Reports By Polaris Market Research:

Cool Roof Coatings Market

Oleochemicals Market

Snow Sport Accessories Market

HDPE Geogrid Market

Oleochemicals Market

Organic Liquid Soap Market

Elastomer Gel in Personal Care Market

3D Motion Capture System Market

Benign Prostatic Hyperplasia Surgical Treatment Market

Pesquisar
Categorias
Leia mais
Outro
Mono-Material Recyclable Stretch Yarn Systems Market Size to Reach USD 2.6 Billion by 2036
The global mono-material recyclable stretch yarn systems market is entering a transformative...
Por monikak 2026-07-09 09:26:31 0 377
Gardening
Native >> https://www.facebook.com/NativePathNativeSynbiotics/
➾SHOP NOW & SAVE! https://nativesynbiotic.com/   NativePath Native Synbiotic - is a...
Por vefecok 2026-10-19 12:38:55 0 301
Outro
Clean Beauty Formulations Transforming the Facial Care Market
Facial Care Market Expands as Skin Health Awareness, Premium Beauty Demand, and Personalized...
Por sakshi11 2026-07-20 12:30:13 0 544
Outro
Industrial Remote Operation Systems Market Boosted by Edge Computing and Cloud Integration: Forecast 2025 - 2035
Industrial Remote Operation Systems Market Overview:     The...
Por prakash045 2026-08-06 07:52:34 0 497
Music
Candle Jar Boxes UK for Better Product Safety and Branding
Candle brands across the UK face a common challenge. Glass candle jars can look attractive on...
Por zdrtgsfyh12 2026-06-24 12:58:05 0 950
AC Mingle https://acmingle.com